0001209191-20-048659.txt : 20200828 0001209191-20-048659.hdr.sgml : 20200828 20200828171534 ACCESSION NUMBER: 0001209191-20-048659 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200610 FILED AS OF DATE: 20200828 DATE AS OF CHANGE: 20200828 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Galante Joseph C CENTRAL INDEX KEY: 0001632384 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33637 FILM NUMBER: 201148726 MAIL ADDRESS: STREET 1: 111 TENTH AVENUE STREET 2: SUITE 200 CITY: NASHVILLE STATE: TN ZIP: 37203 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CUMBERLAND PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001087294 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2525 WEST END AVENUE STREET 2: SUITE 950 CITY: NASHVILLE, STATE: TN ZIP: 37203 BUSINESS PHONE: 615-255-0068 MAIL ADDRESS: STREET 1: 2525 WEST END AVENUE STREET 2: SUITE 950 CITY: NASHVILLE STATE: TN ZIP: 37203 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-06-10 0 0001087294 CUMBERLAND PHARMACEUTICALS INC CPIX 0001632384 Galante Joseph C 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203 1 0 0 0 Common Stock 2020-06-12 4 P 0 225 3.37 A 20992 D Common Stock 2020-06-19 4 P 0 375 3.41 A 21367 D Common Stock 2020-06-26 4 P 0 375 3.37 A 21742 D Common Stock 2020-07-02 4 P 0 300 3.34 A 22042 D Common Stock 2020-07-10 4 P 0 375 3.31 A 22417 D Common Stock 2020-07-17 4 P 0 375 3.29 A 22792 D Common Stock 2020-07-24 4 P 0 375 3.33 A 23167 D Common Stock 2020-07-31 4 P 0 375 3.26 A 23542 D Common Stock 2020-08-07 4 P 0 375 3.42 A 23917 D Common Stock 2020-08-14 4 P 0 375 3.44 A 24292 D Common Stock 2020-08-21 4 P 0 375 3.35 A 24667 D Common Stock 2020-08-26 4 P 0 225 3.29 A 24892 D The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Joseph C. Galante by /s/ Michael Bonner as attorney-in-fact 2020-08-28